Live
Clinical OMICsPrecision, Gene-Edited Antimicrobial Targets Difficult-to-Treat E. ColiClinical OMICsLargest Rare Variant–Lipid Association Study Finds Heart Disease TargetsClinical OMICsWomen’s Memory Decline Linked to ECM Changes from Brain Estrogen LossClinical OMICsVirtual Reality Could Pinpoint Early Signs of Alzheimer’sClinical OMICsMyeloid Malignancy Testing: Insights from a Portuguese Reference CenterBioPharma DiveVerge, following trial failure, rebrands its AI drug discovery ambitionsBioPharma DiveFDA delays decision on AstraZeneca breast cancer pillFierceBiotechKordata Dynamics launches with neural-focused AI clinical trial modelClinical OMICsDual CA19-9 Threshold Improves Risk Stratification in Pancreatic CancerClinical OMICsCD169-Positive Macrophages Attacking Melanoma Imaged in Living TissueClinical OMICsGuardant Nabs Key ACS Nod and Liquid Biopsy ApprovalClinical OMICsAI Foundation Model Maps Tumor Mutations to Predict Cancer Therapy Response
Illumina Apr 12, 2026

Illumina Inc. stock (US4523271090): Is its genomics leadership strong enough for long-term U.S. inve - AD HOC NEWS

Illumina Inc. stock (US4523271090): Is its genomics leadership strong enough for long-term U.S. inve - AD HOC NEWS

Body unavailable. Use the original source.